SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunomedics (IMMU)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Zeev Hed who wrote (8)7/31/1996 2:52:00 AM
From: Zvi Yammer   of 371
 
Spoke with Paul Heron today.
He said they are still assessing the market for pricing, but he thinks that it will be in the 500 - 700 dollar range.
Gross margins he suggested would be similar to pharmacutical company standards which should be in the 65-70% . Since this is being joint maarketted with Mallinkrodt, sales won't commence until end of this Q / beginning of the next,

He expects European approval and FDA submission of Leukoscan within the next 4-8 weeks. My guess is it doesn't pay to submit for FDA if Europe hasn't approved.
He also says that he thinks a paper will be published shortly, this may be the Aug issue that was mentioned here.
things seem to be on track, the market seems to be valuing companies a little more conservatively these days.
Unfortunately, he says only one small brokerage was reccomending the stock. Their price target was 12 which was reached. He;s not sure if they will reiterate the buy now that the stock has falln 50% from its high.
No othter firms that he is aware of follows the company.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News